Post-earnings recap
Reported
Wed, Apr 29, 2026
EPS actual
$0.53
EPS est.
$0.49
EPS surprise
+8.83%
1-day move
+11.89%
Teva Pharmaceutical's earnings report shows a positive surprise in EPS, which may indicate better-than-expected cost management or operational efficiency. However, the stock reaction remained flat, suggesting investors may be waiting for more clarity on revenue performance and future guidance. The lack of revenue data and guidance could lead to uncertainty in the stock's near-term outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.53 | $0.46 | +8.83% |
| Revenue | N/A | $3.8B | N/A |
Management expressed cautious optimism about future performance, focusing on operational improvements. They acknowledged ongoing market challenges but are committed to enhancing product availability.
Management highlighted ongoing efforts to streamline operations.
They emphasized a focus on improving product availability.
The team remains committed to addressing market challenges.
Teva Pharmaceutical Industries Limited is a global leader in the pharmaceutical sector, primarily known for its generic and specialty medications. With a market cap of $36 billion, Teva plays a crucial role in providing affordable healthcare solutions, especially in a time when healthcare costs are a significant concern for consumers and governments alike.
Last quarter
In Q4 2025, Teva reported an EPS of $0.96, significantly beating estimates of $0.63, which led to a positive market reaction. The company's strong performance in the previous quarter may set a favorable tone for this upcoming earnings report.
Management promises and guidance
EPS beat streak
0Q
EPS beat rate
88%
Avg EPS surprise
+6.79%
Avg 1-day reaction
+4.22%
Analysts are generally optimistic about Teva's upcoming earnings, expecting a solid performance based on previous quarters' results. The consensus EPS estimate is $0.46, indicating confidence in the company's ability to maintain profitability.
Bull case
If Teva exceeds the EPS estimate, it would reinforce investor confidence and could lead to a significant stock price increase, similar to past performance where the stock rose after earnings beats.
Bear case
Conversely, if Teva fails to meet expectations, especially after a strong previous quarter, it could lead to a sharp decline in stock price, reflecting investor disappointment.
Key metrics to watch
EPS
0.46Earnings per share is a key indicator of profitability and will show how well Teva is managing its costs and revenues.
Revenue
3.8BTotal revenue will reflect the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Teva's EPS exceed the consensus estimate of $0.46?
A beat on EPS would affirm the company's operational strength and could lead to a positive market reaction.
Q2
How will revenue compare to the consensus estimate of $3.8 billion?
Revenue performance is critical for assessing market demand and the overall health of Teva's business.
—
Est. EPS
$1.52
Est. Rev
$3.6B
Impl. Move
±39.2%
Why consensus could be wrong
The Street may be underestimating Teva's ability to capitalize on emerging market opportunities, which could drive stronger-than-expected revenue growth.
Supporting evidence
Teva's recent product launches may not be fully reflected in current revenue estimates.
The company's cost management strategies could lead to better-than-expected margins.
Options pricing suggests a higher volatility expectation, indicating that traders may anticipate significant news.
Key risk
If revenue comes in above $4.0 billion, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is under scrutiny as investors look for signs of sustained growth and profitability after a strong previous quarter.
Bull confirmed if
An EPS of $0.52 or higher would confirm the bull case, indicating strong operational performance.
Bear confirmed if
An EPS below $0.41 would support the bear case, suggesting potential challenges in profitability.
What the market is pricing for the move.
Implied Move
±11.18%
Historical Avg
±9.5%
The options market is pricing in a significant potential move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±12.6% while TEVA has averaged ±9.5% over the last 8 prints — setup is pricing rich.
ATM IV
1.7%
30d HV
32.8%
Smart-money positioning from the most recent 13F filings.
Institutional
26.37%
of float
Insider
0.56%
of float
Holders
119
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
63,894,301 sh · $2.5B
5.48%
-1.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Teva beats expectations, history suggests the stock could rise by around 2.64%, confirming the company's positive trajectory.
In line / cautious
If results are in line with expectations, the stock may experience a muted response as investors await further guidance.
Miss
A miss could lead to a decline, with historical patterns suggesting an average drop of around 12.83% following earnings misses.
The lines on the call that would change the story.
Harel Insurance Investments & Financial Services Ltd.
48,138,805 sh · $1.9B
4.13%
4.8%
Phoenix Financial Ltd.
42,933,367 sh · $1.7B
3.68%
0.4%
WCM Investment Management, LLC
41,315,232 sh · $1.6B
3.55%
1.2%
Clal Insurance Enterprises Holdings Ltd
40,596,506 sh · $1.6B
3.48%
5.6%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.